Department of Gastroenterology, St George's University Hospital, London, UK.
Center for Digestive Diseases, St James's University Hospital, Leeds, UK.
Am J Gastroenterol. 2014 Jan;109(1):23-34; quiz 35. doi: 10.1038/ajg.2013.402. Epub 2013 Dec 10.
The thiopurine (TP) analogs azathioprine and mercaptopurine have proven efficacy in inducing and maintaining clinical remission in Crohn's disease (CD). Their impact on the long-term need for surgery is uncertain since studies have reported conflicting results. The aim of this systematic review was to summarize and evaluate evidence of the published literature regarding those studies assessing the impact of TPs on the risk of first surgical resection in CD.
We searched Medline, EMBASE, CINAHL, and hand searched reference lists of identified articles, without language restrictions in August 2013.
Seventeen retrospective observational studies (eight population based, three multicenter, and six referral center) representing 21,632 participants met our inclusion criteria. Of these 10 studies involving 12,586 participants provided data on the hazard ratio (HR) and 95% confidence intervals (CIs) evaluating use of TPs and surgical risk. The combined pooled HR of first intestinal resection with TP use was 0.59 (95% CI 0.48-0.73).
TP use is associated with a 40% lowered risk of surgical resection in patients with CD. Despite significant reductions in rates of surgical resection in patients with CD over the last 5 decades and increasing use of TPs, a large proportion of patients with CD still require resectional surgery.
硫嘌呤(TP)类似物硫唑嘌呤和巯嘌呤已被证明可有效诱导和维持克罗恩病(CD)的临床缓解。关于它们对手术长期需求的影响尚不确定,因为研究报告的结果相互矛盾。本系统评价的目的是总结和评估关于评估 TP 对 CD 患者首次手术切除风险影响的已发表文献的证据。
我们于 2013 年 8 月检索了 Medline、EMBASE、CINAHL 和已确定文章的参考文献列表,没有语言限制。
17 项回顾性观察研究(8 项基于人群,3 项多中心,6 项转诊中心)代表了 21632 名参与者,符合我们的纳入标准。其中 10 项研究涉及 12586 名参与者,提供了关于使用 TP 和手术风险的危害比(HR)和 95%置信区间(CI)的数据。使用 TP 的患者首次肠道切除的合并汇总 HR 为 0.59(95%CI 0.48-0.73)。
TP 的使用与 CD 患者手术切除风险降低 40%相关。尽管在过去的 5 十年中 CD 患者的手术切除率显著降低,并且 TP 的使用增加,但仍有很大一部分 CD 患者仍需要进行切除术。